Galenica in 2015: strong sales growth and confirmation of the 20th consecutive increase in profit
Thursday, 21 January 2016, ↓ directly to download
The Galenica Group grew strongly in 2015, increasing consolidated net sales by 11.0% to CHF 3,791.6 million. This growth is broadly based, with contributions from all areas.
Group management has confirmed the forecast communicated in the half-year report 2015 that it will increase profit, both before and after deduction of minority interests, for the 20th consecutive year.
Preparatory work for the transformation of Vifor Pharma and Galenica Santé into two inde-pendent companies is proceeding as planned, with the goal of dividing the Galenica Group in the fourth quarter of 2016.
Vifor Pharma: Ferinject®/Injectafer® shows strong growth in all regions
In 2015, Vifor Pharma increased net sales by 36.9% from the previous year to CHF 967.0 million. In addition to very good organic growth, in particular by Ferinject® of over 33%, the distribution agreement concluded with Roche for Mircera® in the spring has already made a significant contribution with sales of CHF 206.8 million.
Spurred by expansion in the USA, the leading iron product Ferinject®/Injectafer® increased sales by 33.2% to CHF 250.9 million. These sales comprise sales by Vifor Pharma sales affiliates as well as sales by partners. As a result, the outstanding growth trend from the first half of 2015 was improved further still. According to IMS data, global market sales of Ferinject®/Injectafer® (December 2014 to November 2015) totalled approximately CHF 350 million, an increase of 46%. The number of units sold (100 mg) grew worldwide by 49%.
Galenica Santé: new offers, new customers
Galenica Santé recorded sales of CHF 2,891.3 million in 2015, an increase of 3.9%. This is a pleasing result in view of the market environment, with cosmetic products and non-prescription medicines in particular under heavy pressure from the euro exchange rate and consumer tourism.
The newly established Galenica Santé launched new offerings and acquired new customers across all Business sectors. Business was also positively impacted by the widespread flu epidemic in the first half of 2015, as well as the significant increase in high-priced medicines over the course of the year.
The investment of CHF 25 million in the Niederbipp distribution centre allows Galenica Santé capacity for further growth.
Galenica Group consolidated net sales in 2015
(in million CHF)
Health & Beauty
- Products & Brands
Galenica Santé intersegment net sales
Intersegment net sales with other Business units
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
Friday, 23 December 2016
Friday, 9 December 2016
Monday, 28 November 2016
Thursday, 6 October 2016
Friday, 2 September 2016
Head of Corporate Communications
Head Investor Relations